GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Net Margin %

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Net Margin % : -723.00% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Tonix Pharmaceuticals Holding's Net Income for the three months ended in Dec. 2023 was $-27.32 Mil. Tonix Pharmaceuticals Holding's Revenue for the three months ended in Dec. 2023 was $3.78 Mil. Therefore, Tonix Pharmaceuticals Holding's net margin for the quarter that ended in Dec. 2023 was -723.00%.

The historical rank and industry rank for Tonix Pharmaceuticals Holding's Net Margin % or its related term are showing as below:

TNXP' s Net Margin % Range Over the Past 10 Years
Min: -1501.78   Med: -1501.78   Max: -1501.78
Current: -1501.78


TNXP's Net Margin % is ranked worse than
77.7% of 1027 companies
in the Biotechnology industry
Industry Median: -160.92 vs TNXP: -1501.78

Tonix Pharmaceuticals Holding Net Margin % Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Net Margin % Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -1,501.78

Tonix Pharmaceuticals Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -701.30 -723.00

Competitive Comparison of Tonix Pharmaceuticals Holding's Net Margin %

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Net Margin % distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Net Margin % falls into.



Tonix Pharmaceuticals Holding Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Tonix Pharmaceuticals Holding's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-116.658/7.768
=-1,501.78 %

Tonix Pharmaceuticals Holding's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-27.322/3.779
=-723.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tonix Pharmaceuticals Holding  (NAS:TNXP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Tonix Pharmaceuticals Holding Net Margin % Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Traded in Other Exchanges
N/A
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.
Executives
Richard Newcomb Stillwell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman director, 10 percent owner, officer: Chief Executive Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan officer: Chief Medical Officer C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange director
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris officer: Chief Administrative Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes director 74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Headlines

From GuruFocus